Vanda Pharmaceuticals | VNDA - Bienes





Bienes Cambio Fecha
Acadia Pharmaceuticals USD 1.56B 233.42M 2025-12
Agios Pharmaceuticals USD 1.3B 88.48M 2025-12
Akebia Therapeutics USD 376.56M 12.41M 2025-12
Alnylam Pharmaceuticals USD 4.97B 114.67M 2025-12
Anika Therapeutics USD 190.27M 833K 2025-12
Arrowhead Research USD 1.6B 218.89M 2025-12
AstraZeneca USD 114.07B 382M 2025-12
Bristol-Myers Squibb USD 96.89B 2.21B 2025-09
Eli Lilly USD 112.48B 2.46B 2025-12
Enanta Pharmaceuticals USD 329.5M 48.77M 2025-12
Esperion Therapeutics USD 465.89M 101.87M 2025-12
Halozyme Therapeutics USD 2.53B 304.09M 2025-12
Heron Therapeutics USD 255.88M 6.93M 2025-12
Insmed USD 2.26B 96.18M 2025-12
J&J USD 199.21B 6.39B 2025-12
Lexicon Pharmaceuticals USD 184.99M 20.94M 2025-12
Ligand Pharmaceuticals USD 1.56B 83.86M 2025-12
Merck USD 129.55B 12.02B 2025-09
Minerva Neurosciences USD 97.97M 69.88M 2025-12
Moderna USD 12.34B 203M 2025-12
Novartis USD 110.95B 3.66B 2025-12
Pfizer USD 208.73B 2.64B 2025-09
PTC Therapeutics USD 2.9B 255.07M 2025-12
Puma Biotechnology USD 202.86M 7.95M 2025-09
Sangamo BioSciences USD 97.56M 11.39M 2025-06
Sanofi EUR 126.81B 2.99B 2025-12
Takeda JPY 15.41T 938.47B 2025-12
Teva Pharmaceutical Industries USD 40.75B 892M 2025-12
Ultragenyx Pharmaceutical USD 1.53B 341.56M 2025-12
Vanda Pharmaceuticals USD 488.95M 112.19M 2025-12
Veracyte USD 1.41B 38.23M 2025-12